• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20062 / SuperGen Completes Contract to Transition Wyeth Distribution of Nipent® ...

SuperGen Completes Contract to Transition Wyeth Distribution of Nipent® Outside of the U.S.

6 June 2006/in 2006, News

SuperGen Completes Contract to Transition Wyeth Distribution of Nipent® Outside of the U.S.

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2006-06-06 13:56:222016-11-28 13:56:48SuperGen Completes Contract to Transition Wyeth Distribution of Nipent® Outside of the U.S.

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen Receives U.S. Patent For Nipent® (Pentostatin For Injection) Link to: SuperGen Receives U.S. Patent For Nipent® (Pentostatin For Injection) SuperGen Receives U.S. Patent For Nipent® (Pentostatin For Injection) Link to: Mayne Acquires SuperGen’s North American Oncology Products Link to: Mayne Acquires SuperGen’s North American Oncology Products Mayne Acquires SuperGen’s North American Oncology Products
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok